WO2019064941A1

WO2019064941A1 - Chemical agent volatilizing instrument

Info

Publication number: WO2019064941A1
Application number: PCT/JP2018/029628
Authority: WO
Inventors: 礼三上; 諒子大久保
Original assignee: エステー株式会社
Priority date: 2017-09-28
Filing date: 2018-08-07
Publication date: 2019-04-04
Also published as: JP7027093B2; JP2019058612A

Abstract

This chemical agent volatilizing instrument (10) comprises: a sealed bag (20) in which a chemical-agent support body (B) having a volatile chemical agent (Y) supported thereon is sealed; and a container (2) that has a slit (13) and stores the sealed bag (20) storing the chemical-agent support body (B) so that a part of the sealed bag (20) protrudes from the slit (13) to the outside, the slit being of a size that does not allow the chemical-agent support body (B) to pass therethrough and allows the sealed bag (20) to be drawn out.

Description

Drug volatilizer

The present invention relates to a drug volatilization tool for volatilizing a drug such as, for example, an aromatic agent, a deodorant, an insect repellent and the like.

In general, volatile chemicals such as fragrances start volatilization when exposed to air. Therefore, for example, when the fragrance is put into the volatilization container, the fragrance is contained in a sealable bag so as not to touch the air, and the bag is broken at the start of use. Alternatively, the opening of the container containing the fragrance is sealed to break the seal at the start of use.

For example, the fragrance package of Patent Document 1 has a structure in which a bag containing a fragrance is contained in a flexible case. The case uses a gas permeable film as a part thereof. Then, at the start of use of the fragrance package, the bag is pushed together with the case from the outside of the case, the bag is broken, and the vaporization of the fragrance is started through the gas permeable film. For this reason, it is not necessary to open the case once to break the bag, and the volatilization of the fragrance can be started immediately.

However, since the fragrance package of Patent Document 1 volatilizes the drug that has been released by breaking the fragrance package through the gas permeable film, it is a drug whose permeation is difficult due to the characteristics of the gas permeable film In many cases, drug selectivity is limited.

Moreover, according to the fragrance package of Patent Document 1, since the bag is pushed from the outside of the case, it can not be visually confirmed whether the bag is broken. For this reason, volatilization of the fragrance can not be reliably started.

Japanese Utility Model Publication No. 58-48246

The present invention has been made in view of the above-mentioned point, and an object of the present invention is to provide a drug volatilization device which can start volatilization of a drug reliably and easily.

One embodiment of the drug volatilization device of the present invention has a sealed bag in which a drug carrier carrying a drug having volatility is enclosed, and a drug carrier can not pass through and has an extraction hole of a size that allows removal of the sealed bag. And a container containing the sealed bag containing the drug carrier in a state where a part of the sealed bag is protruded from the extraction hole to the outside.

According to one aspect of the present invention, it is possible to provide a drug volatilizer capable of starting the volatilization of a drug reliably and easily.

FIG. 1 is an external perspective view showing a medicine volatilization device according to the embodiment. FIG. 2 is a schematic view showing an attachment example of the drug volatilization device of FIG. FIG. 3 is a schematic perspective view of one container of the drug volatilization device of FIG. 1 developed. FIG. 4 is an external view showing the container of FIG. 3 in an unused state. FIG. 5 is an external view showing a sealed bag according to the first embodiment housed in the container of FIG. 6 is a cross-sectional view of the unused container of FIG. 4 taken along F6-F6. FIG. 7 is an operation explanatory view for explaining an operation of breaking the sealed bag contained in the container of FIG. FIG. 8 is an external view showing a sealed bag according to a second embodiment. FIG. 9 is an operation explanatory view for explaining an operation of breaking the sealed bag of FIG. FIG. 10 is an external view showing a sealed bag according to a third embodiment.

Hereinafter, embodiments of the present invention will be described with reference to the drawings.
As shown in FIG. 1, the drug volatilization device 10 according to the embodiment has a structure in which two substantially

spherical containers

2 and 4 each having a hollow inside are connected by an annular rubber cord 6. The rubber cord 6 does not have to be annular, and may be a single cord-like member, and may not necessarily be made of an expandable material.

In one container 2, a plurality of granular drug carriers (not shown here) carrying microcapsules in which a volatile drug (a fragrance, a deodorant, etc.) is sealed are contained. There is. The drug carrier may be one in which the drug is directly carried on a particulate carrier without using microcapsules, and the drug carrier includes particles in which the drug itself is solidified. The number, shape, and size of the drug carriers can be set arbitrarily, as long as they can move within the container 2 when the container 2 is vibrated.

The other container 4 may contain the drug carrier in the same manner as the container 2 and may not contain the drug carrier. The size and shape of the two

containers

2 and 4 do not have to be the same. The container 4 does not have to be hollow inside. However, in the present embodiment, the container 4 is formed in the same structure as the container 2, and the drug carrier is accommodated inside. In the following description, the structure of one container 2 will be described in detail, and as for the structure of the other container 4, components that function in the same manner as the container 2 will be assigned the same reference numerals and detailed description thereof will be omitted.

For example, as shown in FIG. 2, the drug volatilization tool 10 having the above-described structure may be tied to a headrest 12 of an automobile, tied to a rearview mirror, hooked and attached to a louver at an air outlet, or rear seat It can be used by tying it to the assist grip located above. The chemical volatilizer 10 can be attached to any suspended object other than the component parts of the vehicle.

When the drug volatilization tool 10 is tied to, for example, the headrest 12 of a car seat, the rubber strap 6 is tied to one of the columns 12 a of the headrest 12. The drug volatilization tool 10 of the present embodiment is used by attaching it to a mobile body such as an automobile because the microcapsules carried on the drug carrier are broken and the drug volatilizes by giving vibration to the container 2. It is suitable for

Hereinafter, the structure of the container 2 will be described with reference to FIGS. 3 and 4.
The container 2 has two substantially hemispherical two

transparent resin cases

2a and 2b. The container 2 has a structure in which the edges of the openings of the

resin cases

2a and 2b are fitted to each other, and has a substantially spherical accommodation space for accommodating the drug carrier therein. The two

resin cases

2a and 2b do not necessarily have to be separable structures, and may be integrated. The two

resin cases

2a and 2b are not exactly half balls, and in the present embodiment, the resin case 2a is formed slightly larger than the resin case 2b.

The

resin cases

2a and 2b have a plurality of circular or star-shaped volatilization holes 2c. The volatilization holes 2c are provided through the

resin cases

2a and 2b. The volatilization holes 2c need not necessarily be provided in both of the

resin cases

2a and 2b, and may be provided in at least one of the

resin cases

2a and 2b. Or if the slit 13 mentioned later is used as a volatilization hole, it is not necessary to necessarily provide the volatilization hole 2c. The shape and size of the volatilization holes 2c are designed so as to prevent the drug carrier from passing therethrough. The number, shape and size of the volatilization holes 2c can be set arbitrarily. The

resin cases

2a and 2b do not need to be transparent, and for example, a pattern may be drawn on the surface of the

resin cases

2a and 2b.

As shown in FIG. 3, at the edge of the opening of the smaller (right side in the figure) resin case 2b, two arc-shaped plate-like engaging projections 3, 3 along the shape of the edge are integrated. It is protrusively installed. The two engagement projections 3, 3 are provided at opposite radial opposite sides of the opening and at spaced apart positions. On the outer side in the radial direction of each of the engagement protrusions 3, 3, two

curved engagement claws

3 a, 3 a are provided. The two

engaging claws

3a, 3a of the respective engaging projections 3 are circumferentially separated from each other.

At the edge of the opening of the larger (left side in the drawing) resin case 2a, four engaging claws 5a (only two are shown) are directed inward corresponding to the four engaging claws 3a of the resin case 2b. It has been erected. The respective engaging claws 5a are curved according to the shape of the opening and are provided apart from each other in the circumferential direction. A pressure plate 5 curved along the edge of the opening is provided at a position opposite to the inside of each of the four engagement claws 5a.

Further, two relatively long arc-shaped

concave portions

11, 11 are provided at the edge of the opening of the resin case 2a. These two concave portions 11 are provided at positions in the edge of the opening of the resin case 2a facing each other in the radial direction where the engaging claw 5a and the pressing plate 5 described above are not provided. As shown in FIG. 4, with the two

resin cases

2 a and 2 b fitted, these two

recesses

11 and 11 have slits 13 for inserting both ends of a sealed bag F of a drug carrier B described later, It functions as 13. The depth of the recess 11 is smaller than the diameter of the drug carrier so that the drug carrier does not go out of the container 2 through the slit 13.

When overlapping the openings of the two

resin cases

2a and 2b and fitting the two

resin cases

2a and 2b, the edge of the opening of the resin case 2a with the larger engaging protrusion 3 of the smaller resin case 2b It is inserted into a gap between the pressing plate 5 and pushed in, and the four engaging claws 3a of the resin case 2b and the four engaging claws 5a of the resin case 2a respectively engage with each other. As a result, the two

resin cases

2a and 2b are integrated to form a spherical container 2 as shown in FIG.

Thus, in a state where the two

resin cases

2a and 2b are fitted, the pressing plate 5 suppresses the deformation of the engagement projection 3 so as to hold the engagement by the

engagement claws

3a and 5a, and the resin case 2a, It makes it impossible to separate 2b. However, the pressing plate 5 may be eliminated so that the

resin cases

2a and 2b can be separated.

By the way, two

resin cases

2a and 2b are connected by the plate-shaped connecting member 1 which has flexibility. One end of the connection member 1 is integrally fixed to the outer surface near the edge of the opening of the resin case 2 b at the outer side in the radial direction of the one engagement protrusion 3. The other end of the connecting member 1 is integrally fixed to the outer surface of the resin case 2 a near the edge of the opening between the two pressing plates 5. That is, when the connecting member 1 is bent to fit the two

resin cases

2a and 2b, the connecting member 1 is provided at a position where the corresponding four sets of engaging

claws

3a and 5a face each other.

More specifically, as shown in FIG. 3, the connecting member 1 has a structure in which three

thick portions

7a, 7b, 7c are alternately connected in a line via two

thin portions

8a, 8b. That is, one end (left end in the figure) of thick part 7a is integrally connected to the outer surface of resin case 2a, and the other end of thick part 7a and one end of thick part 7b are foldably connected via thin part 8a. The other end of thick portion 7b and one end of thick portion 7c are foldably connected via thin portion 8b, and the other end (the right end in the figure) of thick portion 7c is integrally connected to the outer surface of resin case 2b. ing.

The connection member 1 is formed by integral molding of one type of resin together with the two

resin cases

2a and 2b. Therefore, the bendability of the

thin portions

8a, 8b is adjusted by selecting the thickness of the

thin portions

8a, 8b. In this embodiment, the two

resin cases

2a and 2b and the connecting member 1 are formed of polypropylene or polyethylene having relatively hinge characteristics (strong in bending). In the present embodiment, the

thin portions

8a and 8b are formed to have a thickness of about 0.2 mm to 0.5 mm.

Each of the three

thick portions

7a, 7b, 7c has a thickness that can hardly deform by itself, and forms a cylinder when the coupling member 1 is annularly curved as shown in FIG. It is curved to the same side. In the present embodiment, the

thick portions

7a, 7b, 7c are formed to have a thickness of about 0.7 mm to 1.5 mm.

At the end where each

thick portion

7a, 7b, 7c communicates with the

thin portions

8a, 8b, a step corresponding to the difference in thickness is provided. The two

thin portions

8a, 8b have an outer surface which is flush with the outer surface 1a of the three

thick portions

7a, 7b, 7c when made annular as shown in FIG. For this reason, the step is formed on the inner surface 1b side between the thick portion and the thin portion.

In other words, this step is provided with the contact end face 9 connecting the

thin portions

8a, 8b of the

thick portions

7a, 7b, 7c. The contact end face 9 of the

thick portions

7a, 7b, 7c is a flat inclined surface extending in the radial direction according to the curvature of the

thick portions

7a, 7b, 7c (that is, the curvature of the cylinder of FIG. 4) As shown in 4, when the connecting member 1 is curved in a cylindrical shape, the contact end faces 9 of the adjacent

thick portions

7a, 7b, 7c contact each other in a plane.

That is, as shown in FIG. 4, when the connecting member 1 is made annular, the contact end faces 9, 9 of the two

thick portions

7a, 7b adjacent to each other through the thin portion 8a are in contact with each other and pressed against each other. The contact end faces 9 and 9 of the two

thick parts

7b and 7c adjacent to each other via the contact 8b are brought into contact with each other and pressed against each other. Thereby, the inner surface 1b of the cylindrical connection member 1 forms a cylindrical surface smoothly connected without any step. For this reason, when the rubber cord 6 is inserted into the cylindrical connection member 1, the wear of the rubber cord 6 can be suppressed, and the service life of the rubber cord 6 can be extended.

Further, in a state where the two

resin cases

2a and 2b are expanded as shown in FIG. 3, the two

thin portions

8a and 8b of the connecting member 1 are on the same side as the three

thick portions

7a, 7b and 7c, It curves so that it may project on the outer surface 1a side in the state made annular as shown in FIG. For this reason, when the connecting member 1 is rolled into a cylindrical shape as shown in FIG. 4, the outer surface 1a of the connecting member 1 becomes a smooth cylindrical surface, and the appearance looks beautiful. In addition, when the

thin portions

8a and 8b are bent so that the

thin portions

8a and 8b protrude toward the outer surface 1a, the

thin portions

8a and 8b are difficult to cut when the connecting member 1 is made annular. It can be made easy to bend.

Hereinafter, the sealed bag of the drug carrier contained in the container 2 having the above-described structure will be described by exemplifying several embodiments. For example, the drug carrier B carrying a drug Y such as a fragrance and a deodorant using microcapsules is stored in a sealed bag so as not to start the volatilization of the drug Y at an undesirable timing. Housed inside. Then, when the use of the drug volatilization device 10 is started, the sealed bag is broken to release the drug carrier B into the container 2.

First Embodiment
FIG. 5 is an external view showing the sealed bag 20 according to the first embodiment. Since the sealed bag 20 is formed of a transparent resin film, the drug carrier B housed inside can be seen from the outside. FIG. 4 shows a state in which both ends 20a and 20b of the sealed bag 20 protrude from the

slits

13 and 13 to the outside of the container 2, respectively. The slit 13 functions as an extraction hole for extracting the sealed bag 20, and also functions as a lead-out hole for discharging a part of the sealed bag 20. 6 is a cross-sectional view of the unused container 2 containing the sealed bag 20 therein, taken along line F6-F6 of FIG.

As shown in FIG. 5, the sealing bag 20 is, for example, a cylindrical resin film formed into a cylindrical shape, two end sides thereof overlapped, and sealed by the seal portion S1 to form a cylindrical resin film (hereinafter referred to as a cylindrical (Hereinafter referred to as “poly film”) is sealed by the seal portion S2. The drug carrier B is inserted into the tubular film from the other end side after the one end of the tubular film sealed by the sealing portion S1 is sealed by the sealing portion S2. Thereafter, the other end of the tubular film is sealed by the seal portion S2.

The sealing bag 20 is formed, for example, by bonding a resin film, which is formed by overlapping two sheets at the seal portions S1 and S2, by heat welding using a transparent resin film such as polyethylene, polypropylene or polyethylene terephthalate. The adhesion at the seal portions S1 and S2 is not limited to heat welding, and adhesion using an adhesive may be employed.

The adhesive strength of the resin film at the seal portion S2 of at least one of the seal portions S1 and S2 is relatively weak, and the drug carrier B accommodated in the inside is pressed against the seal portion S2 from the inside of the sealed bag 20. It is set to the extent that it can be sealed. In this case, the seal portion S2 (and / or S1) functions as an easy-to-seal portion.

The drug carrier B contained in the sealed bag 20 is, for example, a perfume impregnated body impregnated with a slurry containing microcapsules encapsulating a drug. As the perfume impregnated body, for example, Bisco Pearl (trade name) which is a porous cellulose particle, paper, flow light which is a porous calcium silicate particle, EVA (ethylene vinyl acetate copolymer) beads and the like are used. The microcapsules are torn off when external pressure is applied to release the drug encapsulated inside. The slurry containing the microcapsules is impregnated in the perfume impregnated body and applied to the surface, so that the microcapsules break up when pressure is applied from the outside of the perfume impregnated body. At this time, the external pressure includes pressurization by contact such as friction.

The sealed bag 20 containing and sealing the plurality of drug carriers B as described above is housed and held in the container 2 in the state shown in FIGS. 4 and 6. First, as shown in FIG. 3, the sealed bag 20 is placed in the larger resin case 2a of the two

resin cases

2a and 2b in which the container 2 is expanded, and the width of both ends 20a and 20b of the sealed bag 20 is narrowed. As it is contracted, it is put on each of the two concave portions 11 and made to project to the outside. In this state, the smaller resin case 2b is fitted to the resin case 2a. Thereby, the sealed bag 20 is held in the container 2 in a state where the both ends 20a, 20b protrude outward from the

slits

13, 13.

The width of the sealed bag 20 is made larger than the width W (FIG. 3) of the slit 13. The width W of the slit 13 mentioned here is a linear distance between both ends of the slit 13. In this manner, by making the width of the sealing bag 20 larger than the slit 13, wrinkles occur at the portions where both ends 20a and 20b of the sealing bag 20 pass through the slit 13 in the unused state (state shown in FIGS. 4 and 6). Thus, the problem that the

end portions

20a and 20b of the sealed bag 20 fall into the container 2 through the slits 13 can be prevented. Further, by making the width of the sealed bag 20 larger, the opening can be made relatively large when the medicine carrier B is accommodated in the tubular film, and the workability can be enhanced.

Moreover, in the present embodiment, the drug carrier B stored in the sealed bag 20 with respect to the volume of the container 2 so that the

end portions

20a and 20b of the sealed bag 20 do not fall into the container 2 in the unused state described above. Set the amount of When the number of drug carriers B contained in the sealed bag 20 is small, a large space is created between the container 2 and the sealed bag 20, and the drug carrier B is inserted with the both ends 20a and 20b of the sealed bag 20 through the slits 13. The weight of the body B increases the distance by which the sealed bag 20 hangs toward the inner surface of the container 2. That is, in this case, the amount by which the

end portions

20a and 20b of the sealed bag 20 are drawn into the container 2 increases, and the

end portions

20a and 20b easily come out of the slit 13. Therefore, in the present embodiment, the number of drug carriers B is increased, and the drooping distance by self weight is shortened.

On the other hand, as shown in FIG. 6, with the both ends 20a, 20b of the sealed bag 20 held by the

slits

13, 13, if there is a gap between the inner surface of the container 2 and the sealed bag 20, transport of the drug volatilization tool 10 The impact applied to the drug carrier B can be mitigated when, for example, the drug volatilization tool 10 is dropped. Therefore, the number of drug carriers B is such that a certain amount of space is formed between the container 2 and the sealed bag 20 in a state where the sealed bag 20 is held by the slits 13 in the state of FIG. It is desirable to

Besides, in order to prevent the both ends 20a and 20b of the sealed bag 20 from falling off the

slits

13 and 13, the resin film itself of the sealed bag 20 is thickened, or the

end portions

20a and 20b pass the height of the slit 13. It is also conceivable to set the height as low as possible. Further, the length from the slits 13 of the both ends 20a and 20b of the sealed bag 20 may be extended outward to prevent the detachment from the slits 13.

Hereinafter, with reference to FIG. 7, the method of tearing the sealed bag 20 in the unused container 2 described above will be described.
First, as shown in FIG. 7A, one end 20b of the sealed bag 20 projecting outward from the slit 13 (extraction hole) on one side (right side in the drawing) of the container 2 is pulled. Thereby, the other end 20a of the sealed bag 20 enters the inside of the container 2, and the drug carrier B is offset to the other end 20a side. By pulling the end 20b, the volume of the sealed bag 20 gradually decreases.

Then, when the volume of the sealed bag 20 becomes smaller than the volume of the space occupied by the drug carrier B, the internal pressure of the sealed bag 20 increases as shown in FIG. 7B, and the seal portion S2 at the other end 20a is peeled off. Thus, the sealed bag 20 is broken, and the drug carrier B is released into the container 2. At this time, the seal portion S1 may peel in addition to the seal portion S2 peeling, or the seal portion S1 may peel instead of the seal portion S2. The drug carrier B needs to have a size that can not pass through the slit 13.

When one end 20 b is further pulled, the resin film of the sealed bag 20 is completely pulled out of the slit 13 and separated from the container 2 as shown in FIG. 7 (c). In this state, the drug carrier B is released into the container 2 and touches the air, so that the drug carrier B becomes movable in the container 2 and volatilization of the drug Y is started.

As described above, according to the present embodiment, it is possible to seal the sealing bag simply by pulling the end 20 b (or 20 a) of the sealing bag 20 protruding outward from one of the two slits 13 of the container 2. Only twenty resin films can be separated from the container 2. Therefore, the drug carrier B can be reliably and easily released into the container 2, and the volatilization of the drug Y can be reliably started.

Further, according to the present embodiment, the user does not touch the drug carrier B at the start of use of the drug volatilization device 10, so the user can touch the drug Y carried on the drug carrier B or the drug It is possible to prevent the problem of dropping the carrier B out of the container 2.

Further, according to the present embodiment, since the resin film of the sealed bag 20 is removed from the slit 13 at the start of volatilization of the drug Y, there is no need to open the container 2 at the end of use of the drug volatilization tool 10 and take out the resin film. Disposal of the tool 10 can be facilitated.

Furthermore, according to the present embodiment, unlike the prior art, since it is not necessary to use a gas permeable film, the kind of the drug Y to be carried on the drug carrier B can be freely selected, and any kind of drug volatilization device 10 can be selected. The drug Y can be volatilized.

In the first embodiment described above, although the case where both ends 20a and 20b of the sealed bag 20 in which the drug carrier B is sealed with the resin film is drawn out from the slit 13, it is not limited thereto. The container 2 may be provided with a single slit 13 and one end of the sealed bag 20 may be led out from the slit 13. In this case, the other end of the sealed bag 20 will be located in the container 2, and when tearing the sealed bag 20, the end of the sealed bag 20 drawn out from the single slit 13 is pulled out. become.

Second Embodiment
FIG. 8 is an external view showing a sealed bag 30 according to the second embodiment. The sealed bag 30 is housed in the container 2 in the same manner as the sealed bag 20 of the first embodiment described above, and is broken at the start of use of the drug volatilizer 10.

In the sealing bag 30 of the present embodiment, for example, in a state where a plurality of drug carriers B are accommodated inside, a rectangular resin film is folded in half at the center, and the resin is used at the sealing portion S3 overlapped at three released sides. It forms by welding films. In addition, the sealed bag 30 has two notches K, K disposed outside the container 2 with the both ends 30a, 30b protruding outward from the

slits

13, 13 housed in the container 2 . The notches K are provided in the seal portion S3 of the sealed bag 30 in the vicinity of both

longitudinal ends

30a and 30b of the sealed bag 30.

In the case of using the drug volatilization tool 10 in which the above-mentioned sealed bag 30 is accommodated in the container 2, first, as shown in FIG. 9A, it protrudes outward from the slit 13 (lead hole) on one side (left side in the figure) A portion of the sealed bag 30 is cut and torn from a notch K near the end 30a of the sealed bag 30. The drug carrier B accommodated in the container 2 has a size that can not pass through the slit 13. Therefore, even if the sealed bag 30 is broken, the drug carrier B is not released to the outside of the container 2.

Thereafter, as shown in FIG. 9B, the resin film of the sealed bag 30 is pulled out of the slit 13 by pulling the end 30b of the sealed bag 30 opposite to the cut end 30a. At this time, the drug carrier B remains in the container 2 as in the first embodiment.

Further, when the resin film is pulled, the resin film of the sealed bag 30 is completely separated from the container 2 as shown in FIG. 9 (c).

As described above, also in the present embodiment, as in the first embodiment described above, the resin film of the sealed bag 30 can be easily extracted from the container 2 and the volatilization of the drug Y can be reliably started. it can.

Third Embodiment
FIG. 10 is an external view showing a sealing bag 40 according to the third embodiment.
The sealing bag 40 has the same structure as the sealing bag 30 of the second embodiment described above except that it has a perforation T at the center in the longitudinal direction instead of the notch K. Therefore, the same numerals are given to the composition which functions like a 2nd embodiment, and the detailed explanation is omitted here.

When the sealed bag 40 is broken and the use of the drug volatilization tool 10 is started, the

ends

40a and 40b of the sealed bag 40 respectively projected outward from the two slits 13 of the container 2 are pulled in opposite directions with both hands. Thereby, the resin film of the sealed bag 40 is torn at the perforation T and separated into two. The two separated resin films are respectively pulled out of the container 2 through the slits 13. Thereby, the drug carrier B is released into the container 2 and volatilization of the drug Y is started.

As described above, also in the present embodiment, the same effects as those of the first and second embodiments described above can be obtained.

The present invention is not limited to the above embodiment, and can be variously modified in the implementation stage without departing from the scope of the invention. In addition, the embodiments may be implemented in combination as appropriate as possible, in which case the combined effect is obtained. Furthermore, the above embodiments include inventions of various stages, and various inventions can be extracted by an appropriate combination of a plurality of disclosed configuration requirements.

For example, in the embodiment described above, the case where the two

slits

13, 13 are provided in the container 2 as the extraction holes for extracting the resin films of the sealed

bags

20, 30, 40 from the container 2 has been described. The shape of the extraction hole of the resin film may be any shape as long as at least the drug carrier B can not pass through.

Claims

A sealed bag containing a drug carrier carrying a drug having volatility;
The drug carrier is accommodated in such a state that the drug carrier can not pass through and the extraction hole has a size capable of extracting the sealed bag, and a part of the sealed bag is protruded from the extraction hole to the outside. A container containing the sealed bag;
Drug volatilizer with.
It further has a volatilization hole provided in the container,
The drug volatilization device of claim 1.
The sealed bag has an easy-to-bag portion that is broken by pulling a part of the sealed bag protruding from the extraction hole.
The drug volatilization device of claim 1.
The easy-to-bag portion is a seal portion of the sealed bag,
The drug volatilization device of claim 3.
The easy-to-bag portion is a perforation provided in the sealed bag,
The drug volatilization device of claim 3.
The container further includes a lead-out hole sized so that the drug carrier can not pass and the other part of the sealed bag can be led out.
The other part of the sealed bag led out through the outlet hole has a notch for breaking the sealed bag,
The drug volatilization device of claim 1.